Kinetics of inhibition of HIV type 1 reverse transcriptase-bearing NRTI-associated mutations by apricitabine triphosphate

Antiviral Chemistry and Chemotherapy

Volumn 18, Issue 2, 2007, Pages 93-101

  Frankel, Fernando A ^a,b   Coutsinos, Dimitrios ^a,b   Xu, Hongtao ^a   Wainberg, Mark A ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Drug resistance; HIV 1; K65R; Subtypes

Indexed keywords

APRICITABINE TRIPHOSPHATE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; STEADY STATE;

EID: 34249317644     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020701800205     Document Type: Article

References (46)

1. Arion D & Parniak MA (1999) HIV resistance to zidovudine: the role of pyrophosphorolysis. Drug Resistance Updates 2:91-95.
2. Boucher S, Recordon-Pinson P, Ragnaud JM, Dupon M, Fleury H & Masquelier B (2006) HIV-1 reverse transcriptase (RT) genotypic patterns and treatment characteristics associated with the K65R RT mutation. HIV Medicine 7:294-298.
3. Boyer PL, Sarafianos SG, Arnold E & Hughes SH (2001) Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. Journal of Virology 75:4832-4842.
4. Brenner BG, Oliveira M, Doualla-Bell F, Moisi DD, Ntemgwa M, Frankel F, Essex M & Wainberg MA (2006) HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 20:F9-F13.
5. Cahn P, Cassetti I, Wood R, Phanuphak P, Shiveley L, Bethell RC Sc Sawyer J (2006) Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients. AIDS 20:1261-1268.
6. Cheung PK, Wynhoven B & Harrigan PR (2004) 2004: which HIV-1 drug resistance mutations are common in clinical practice? AIDS Reviews 6:107-116.
7. de Muys JM, Gourdeau H, Nguyen-Ba N, Taylor DL, Ahmed PS, Mansour T, Locas C, Richard N, Wainberg MA & Rando RF (1999) Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2′-deoxy-3′-oxa-4′-thiocytidine. Antimicrobial Agents & Chemotherapy 43:1835-1844.
8. Deval J, Navarro JM, Selmi B, Courcambeck J, Boretto J, Halfon P, Garrido-Urbani S, Sire J & Canard B (2004a) A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions. Journal of Biological Chemistry 279:25489-25496.
9. Deval J, White KL, Miller MD, Parkin NT, Courcambeck J, Halfen P, Selmi B, Boretto J & Canard B (2004b) Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. Journal of Biological Chemistry 279:509-516.
10. Doualla-Bell F, Avalos A, Gaolathe T, Mine M, Gaseitsiwe S, Ndwapi N, Novitsky VA, Brenner B, Oliveira M, Moisi D, Moffat H, Thior I, Essex M & Wainberg MA (2006) Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen. Antimicrobial Agents and Chemotherapy 50:2210-2213.
11. Frankel FA, Marchand B, Turner D, Gotte M & Wainberg MA (2005) Impaired Rescue of Chain-Terminated DNA Synthesis Associated with the L74V Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase. Antimicrobial Agents & Chemotherapy 49:2657-2664.
12. Girouard M, Diallo K, Marchand B, McCormick S & Gotte M (2003) Mutations E44D and V118I in the reverse transcriptase of HIV-1 play distinct mechanistic roles in dual resistance to AZT and 3TC. Journal of Biological Chemistry 278:34403-34410.
13. Goldschmidt V & Marquet R (2004) Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs). The International Journal of Biochemistry & Cell Biology 36:1687-1705.
14. Gotte M, Arion D, Parniak MA & Wainberg MA (2000) The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. Journal of Virology 74:3579-3585.
15. Gotte M, Kameoka M, McLellan N, Cellai L & Wainberg MA (2001) Analysis of efficiency and fidelity of HIV-1 (+)-strand DNA synthesis reveals a novel rate-limiting step during retroviral reverse transcription. Journal of Biological Chemistry 276:6711-6719.
16. Gu Z, Allard B, de Muys JM, Lippens J, Rando RF, Nguyen-Ba N, Ren C, McKenna P, Taylor DL & Bethell RC (2006) In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection. Antimicrobial Agents & Chemotherapy 50:625-631.
17. Gu Z, Arts, EJ, Parniak MA & Wainberg MA (1995) Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2′,3′- dideoxycytidine 5′-triphosphate and other drugs. Proceedings of the National Academy of Sciences of the United States of America 92:2760-2764.
18. Gu Z, Gao Q, Fang H, Salomon H, Parniak MA, Goldberg E, Cameron J & Wainberg MA (1994) Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′- thiacytidine. Antimicrobial Agents & Chemotherapy 38:275-281.
19. Gu Z, Wainberg MA, Nguyen-Ba N, L'Heureux L, de Muys JM, Bowlin TL & Rando RF (1999) Mechanism of action and in vitro activity of 1′,3′-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants. Antimicrobial Agents & Chemotherapy 43:2376-2382.
20. Harrigan PR, Stone C, Griffin P, Najera I, Bloor S, Kemp S, Tisdale M & Larder B (2000) Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group. The Journal of Infectious Diseases 181:912-920.
21. Hubner A, Kruhoffer M, Grosse F & Krauss G (1992) Fidelity of human immunodeficiency virus type I reverse transcriptase in copying natural RNA. Journal of Molecular Biology 223:595-600.
22. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A & Richman DD (2004) Update of the Drug Resistance Mutations in HIV-1: 2004. Topics in HIV Medicine 12:119-124.
23. Krebs R, Immendorfer U, Thrall SH, Wohrl BM & Goody RS (1997) Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC. Biochemistry 36:10292-10300.
24. Le Grice SF & Gruninger-Leitch F (1990) Rapid purification of homodimer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography. European Journal of Biochemistry 187:307-314.
25. Liang C, Rong L, Gotte M, Li X, Quan Y, Kleiman L & Wainberg MA (1998) Mechanistic studies of early pausing events during initiation of HIV1I reverse transcription. Journal of Biological Chemistry 273:21309-21315.
26. Locatelli GA, Cancio R, Spadari S & Maga G (2004) HIV-1 reverse transcriptase inhibitors: current issues and future perspectives. Current Drug Metabolism 5:283-290.
27. Martin JL, Wilson JE, Haynes RL & Furman PA (1993) Mechanism of resistance of human immunodeficiency virus type 1 to 2′,3′- dideoxyinosine. Proceedings of the Natural Academy of Sciences of the United States of America 90:6135-6139.
28. Meyer PR, Matsuura SE, Mian AM, So AG & Scott WA (1999) A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Molecular Cell 4:35-43.
29. Miller MD (2004) K65R, TAMs and tenofovir. AIDS Reviews 6:22-33.
30. Miller MD, Margot NA, Hertogs K, Larder B & Miller V (2001) Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples. Nucleosides, Nucleotides & Nucleic Acids 20:1025-1028.
31. Miller V, Ait-Khaled M, Stone C, Griffin P, Mesogiti D, Cutrell A, Harrigan R, Staszewski S, Katlama C, Pearce G & Tisdale M (2000) HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS 14:163-171.
32. Miranda LR, Gotte M & Kuritzkes DR (2005) The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations. Antimicrobial Agents & Chemotherapy 49:2648-2656.
33. Morens DM, Folkers GK & Fauci AS (2004) The challenge of emerging and re-emerging infectious diseases. Nature 430:242-249.
34. Parikh UM, Bacheler L, Koontz D & Mellors JW (2006a) The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. Journal of Virology 80:4971-4977.
35. Parikh UM, Barnas DC, Faruki H & Mellors JW (2006b) Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level. Journal of Infectious Diseases 194:651-660.
36. Preston BD, Poiesz BJ & Loeb LA (1988) Fidelity of HIV-1 reverse transcriptase. Science 242:1168-1171.
37. Quan Y, Brenner BG, Marlink RG, Essex M, Kurimura T & Wainberg MA (2003) Drug resistance profiles of recombinant reverse transcriptases from human immunodeficiency virus type 1 subtypes A/E, B, and C. AIDS Research and Human Retroviruses 19:743-753.
38. Richar N, Quan Y, Salomon H, Hsu M, Bedard J, Harrigan PR, Rando R, Mansour T, Bowlin TL & Wainberg MA (1999) Selection and characterization of HIV-1 variants resistant to the (+) and (-) enantiomers of 2′-deoxy- 3′-oxa-4′-thiocytidine (dOTC). Antiviral Therapy 4:171-177.
39. Richard N, Salomon H, Oliveira M, Rando R, Mansour T, Gu Z & Wainberg MA (2000) Selection of resistance-conferring mutations in HIV-1 by the nucleoside reverse transcriptase inhibitors (+/-) dOTC and (+/-)dOTFC. Antiviral Chemistry & Chemotherapy 11:359-365.
40. Spira S, Wainberg MA, Loemba H, Turner D & Brenner BG (2003) Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. Journal of Antimicrobial Chemotherapy 51:229-240.
41. Taylor DL, Ahmed PS, Tyms AS, Wood LJ, Kelly LA, Chambers P, Clarke J, Bedard J, Bowlin TL & Rando RF (2000) Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2′-deoxy-3′-oxa-4′-thiocytidine, dOTC]. Antiviral Chemistry & Chemotherapy 11:291-301.
42. Wainberg MA, Miller MD, Quan Y, Salomon H, Mulato AS, Lamy PD, Margot NA, Anton KE & Cherrington JM (1999) In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antiviral Therapy 4:87-94.
43. Wainberg MA, Sawyer JP, Montaner JS, Murphy RL, Kuritzkes DR & Raffi F (2005) Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection. Antiviral Therapy 10:13-28.
44. White KL, Margot NA, Ly JK, Chen JM, Ray AS, Pavelko M, Wang R, McDermott M, Swaminathan S & Miller MD (2005) A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT. AIDS 19:1751-1760.
45. White KL, Margot NA, Wrin T, Petropoulos CJ, Miller MD & Naeger LK (2002) Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrobial Agents & Chemotherapy 46:3437-3446.
46. Zhang D, Caliendo AM, Eron JJ, DeVore KM, Kaplan JC, Hirsch MS & D'Aquila RT (1994) Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimiaobial Agents & Chemotherapy 38:282-287.